Expert Ratings For Genmab
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Genmab (NASDAQ:GMAB) over the past three months, with a recent decrease in the average 12-month price target by 3.81%. Despite this, Genmab shows strong financial health with impressive revenue growth, net margin, ROE, and ROA, and a low debt-to-equity ratio.
September 09, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Genmab has received mixed analyst ratings, with a decrease in the average price target by 3.81%. However, the company shows strong financial performance with significant revenue growth and profitability metrics.
The mixed analyst ratings and decrease in price target suggest a neutral short-term impact on Genmab's stock. However, the company's strong financial performance, including high revenue growth and profitability, may offset negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100